Blog
RSS FeedPosted by Michael Wonder on 16 Nov 2020
How will Brexit affect the supply of medicines?
6 November 2020 - Starting from day one, 1 January 2021, the government expects new checks and bureaucracy at the short ...
Posted by Michael Wonder on 12 Nov 2020
Expertise, experience, and excellence. Twenty years of patient involvement in health technology assessment at NICE: an evolving story
10 November 2020 - From its inception in 1999, NICE committed to including the expertise, experiences, and perspectives of lay people, ...
Posted by Michael Wonder on 12 Nov 2020
NICE recommends innovative treatment for severe blood disorder for NHS use
12 November 2020 - Caplacizumab, with plasma exchange and immunosuppression, will be used to treat acute acquired thrombotic thrombocytopenic purpura. ...
Posted by Michael Wonder on 11 Nov 2020
NICE publishes draft guidance on new treatment for patients with immune thrombocytopenia
11 November 2020 - The Department of Health and Social Care has asked NICE to produce guidance on using fostamatinib in ...
Posted by Michael Wonder on 10 Nov 2020
NICE recommends new chemotherapy free treatment option for people with untreated chronic lymphocytic leukaemia
10 November 2020 - More than 1,000 people each year will benefit from NICE's recommendation. ...
Posted by Michael Wonder on 09 Nov 2020
Vary drug prices for different conditions, say health experts
9 November 2020 - The NHS could improve patients’ access to new cancer treatments by paying different prices for drugs ...
Posted by Michael Wonder on 09 Nov 2020
NICE issues positive Final Appraisal Determination for AbbVie’s Rinvoq (upadacitinib) in severe active rheumatoid arthritis
6 November 2020 - Positive recommendation means upadacitinib will be available to those with previously treated severe active rheumatoid arthritis. ...
Posted by Michael Wonder on 08 Nov 2020
Midostaurin for treating advanced systemic mastocytosis
6 November 2020 - The Department of Health and Social Care has asked NICE to produce guidance on using midostaurin in ...
Posted by Michael Wonder on 06 Nov 2020
NICE’s methods of technology evaluation - presenting a case for change
6 November 2020 - NICE has today launched a public consultation on proposals for changes to the methods it uses to ...
Posted by Michael Wonder on 05 Nov 2020
Cost effectiveness of cancer drugs: comparative analysis of the United States and England
5 November 2020 - England's National Institute for Health and Care Excellence and the US’ Institute for Clinical and Economic Review ...
Posted by Michael Wonder on 05 Nov 2020
Skin cancer drug not cost effective for routine NHS use
5 November 2020 - A consultation on the draft recommendations has now begun until Tuesday 24 November 2020. ...
Posted by Michael Wonder on 04 Nov 2020
NICE updates guidance for nivolumab for melanoma
4 November 2020 - NICE has updated its guidance for nivolumab for adjuvant treatment of completely resected melanoma with lymph ...
Posted by Michael Wonder on 04 Nov 2020
NICE publishes first technology assessment guidance for oesophageal cancer
4 November 2020 - NICE publishes more guidance on the use of nivolumab. ...
Posted by Michael Wonder on 02 Nov 2020
NICE talking to you: trends in early HTA engagement
29 October 2020 - In 2009, NICE was one of the first health technology assessment agencies to offer the opportunity ...
Posted by Michael Wonder on 02 Nov 2020
On the integration of early health technology assessment in the innovation process: reflections from five stakeholders
28 October 2020 - Early health technology assessment, which includes all methods used to inform industry and other stakeholders about the ...